__timestamp | Ultragenyx Pharmaceutical Inc. | Vericel Corporation |
---|---|---|
Wednesday, January 1, 2014 | 10811000 | 13774000 |
Thursday, January 1, 2015 | 33001000 | 22479000 |
Friday, January 1, 2016 | 64936000 | 27388000 |
Sunday, January 1, 2017 | 99909000 | 35610000 |
Monday, January 1, 2018 | 127724000 | 49007000 |
Tuesday, January 1, 2019 | 161524000 | 61139000 |
Wednesday, January 1, 2020 | 182933000 | 68836000 |
Friday, January 1, 2021 | 219982000 | 97592000 |
Saturday, January 1, 2022 | 278139000 | 106903000 |
Sunday, January 1, 2023 | 309799000 | 120998000 |
Cracking the code
In the dynamic world of biotechnology, understanding financial trends is crucial. This article delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Ultragenyx Pharmaceutical Inc. and Vericel Corporation, from 2014 to 2023.
Ultragenyx has seen a staggering increase in SG&A expenses, growing nearly 2,800% over the decade. This reflects their aggressive expansion and investment in administrative capabilities, crucial for supporting their innovative therapies.
Vericel, while smaller, has also experienced a significant rise in SG&A expenses, increasing by approximately 780%. This growth underscores their commitment to scaling operations and enhancing market presence.
Both companies show a consistent upward trend, with Ultragenyx's expenses peaking at over 2.5 times that of Vericel by 2023. This financial trajectory highlights the competitive nature of the biotech industry, where strategic spending is key to sustaining growth and innovation.
SG&A Efficiency Analysis: Comparing Johnson & Johnson and Ultragenyx Pharmaceutical Inc.
Amgen Inc. vs Vericel Corporation: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Ultragenyx Pharmaceutical Inc.
Regeneron Pharmaceuticals, Inc. and Vericel Corporation: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc.
United Therapeutics Corporation vs Vericel Corporation: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Selling, General, and Administrative Costs: Viatris Inc. vs Ultragenyx Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of Summit Therapeutics Inc. and Vericel Corporation
Cost Management Insights: SG&A Expenses for Insmed Incorporated and Vericel Corporation
Alkermes plc or Ultragenyx Pharmaceutical Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Vericel Corporation and HUTCHMED (China) Limited